0 0 0 0 3.38232061016756E-05 0.00015220442745754 0.00015220442745754 0.00015220442745754
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Following a week where the broader market witnessed a 2.7% rise, Regeneron's stock nudged up 1.86%. Although the company's announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market's overall positive momentum, partly buoyed by robust tech earnings and AI investment disclosures, appears to have largely contributed to its share performance. Regeneron's strategic financial moves, including dividends and buybacks, offer investors noteworthy reasons for confidence. Buy, Hold or Sell Regeneron Pharmaceuticals? View our complete analysis and fair value estimate and you decide. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent news about Regeneron Pharmaceuticals, including the European approval of Lynozyfic™ and advancements in cancer and respiratory treatments, positions the company for potential increased investor interest. While [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Following a week where the broader market witnessed a 2.7% rise, Regeneron's stock nudged up 1.86%. Although the company's announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market's overall positive momentum, partly buoyed by robust tech earnings and AI investment disclosures, appears to have largely contributed to its share performance. Regeneron's strategic financial moves, including dividends and buybacks, offer investors noteworthy reasons for confidence. Buy, Hold or Sell Regeneron Pharmaceuticals? View our complete analysis and fair value estimate and you decide. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent news about Regeneron Pharmaceuticals, including the European approval of Lynozyfic™ and advancements in cancer and respiratory treatments, positions the company for potential increased investor interest. While [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS